Vertex Pharmaceuticals Inc. and NHS England have finally agreed a deal to give patients access to the company’s cystic fibrosis drugs. As well as offering taxpayers value for money for Orkambi (lumacaftor/ivacaftor), Symkevi (tezacaftor/ivacaftor) and Kalydeco (ivacaftor), the company also agreed to submit its products to the health technology appraisal (HTA) processes it had previously resisted. Those appraisals will be informed by real world data.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?